Combined inhibition of receptor glycosylation by fluvastatin or tunicamycin with TKI AC220 caused synergistic cell killing, which was highly selective for cell lines and primary AML cells expressing FLT3 ITD [121]. This evidence concerns the gene FLT3 and acute myeloid leukemia.